For the peptide industry, the implications are enormous: Increased pharmaceutical investment Accelerated peptide innovation Greater public awareness Expansion of metabolic research New generations of multi-pathway therapeutics The peptide era is no longer emerging
The states Group Insurance Commission voted in February to drop coverage of the GLP-1 medications, when used solely for weight management
According to clinical data on semaglutide dosing and weight trends, around 25 percent of patients on lower doses experienced weight gain, while higher doses were linked to greater weight loss
PARP inhibitors: synthetic lethality in the clinic
Removal of Emerging Contaminants (CECs) One of the key advantages of BAC in reuse applications is its ability to remove contaminants of emerging concern (CECs), such as pharmaceuticals, personal care products, endocrine-disrupting compounds (EDCs), and PFAS